januari
second
child
nine
respond
posit
gene
therapi
trial
sever
combin
immunodefici
scid
develop
leukaemia
roughli
month
lead
temporari
moratorium
gene
therapi
trial
involv
introduct
retrovir
vector
haematopoiet
cell
us
fda
advisori
committe
later
recommend
trial
reevalu
casebycas
basi
suspicion
retrovir
vector
modifi
gene
respons
effect
confirm
studi
show
case
vector
integr
near
promot
encod
transcript
factor
requir
haematopoiesi
led
uncontrol
clonal
prolifer
matur
cell
nonrandom
insert
suggest
either
physic
hotspot
integr
locu
like
say
studi
author
random
insert
confer
select
advantag
cell
prolifer
februari
approv
rosuvastatin
crestor
astrazeneca
canada
began
topsyturvi
year
drug
bill
potent
statin
avail
receiv
approv
countri
includ
unit
state
hypercholesterolaemia
end
novemb
rosuvastatin
us
new
prescript
market
statin
compani
said
line
expect
howev
germani
spain
norway
withdrew
approv
process
owe
safeti
concern
situat
similar
case
rhabdomyolysi
observ
cerivastatin
baycol
bayer
market
withdraw
addit
editori
lancet
novemb
critic
astrazeneca
campaign
promot
rosuvastatin
note
market
data
base
trial
surrog
endpoint
clinic
endpoint
wherea
use
current
popular
statin
simvastatin
zocor
merck
atorvastatin
lipitor
pfizer
support
larg
trial
clinic
endpoint
astrazeneca
ceo
sir
tom
mckillop
respond
data
never
avail
cholesterollow
medicin
launch
compani
submit
approv
largest
clinic
databas
statin
march
mysteri
pneumonialik
ill
transmit
doctor
guangdong
region
china
stay
hong
kong
hotel
spread
becom
epidem
becam
known
sever
acut
respiratori
syndrom
sar
sar
affect
report
peopl
patient
kill
spread
mani
countri
includ
singapor
canada
unit
state
make
first
epidem
transmit
air
travel
world
health
organ
declar
march
outbreak
worldwid
health
threat
trigger
unpreced
intern
effort
identifi
caus
agent
highlight
technolog
advanc
made
mani
research
techniqu
compar
twoandahalf
year
took
identifi
hiv
caus
agent
aid
within
month
coronaviru
identifi
infecti
agent
sar
genom
sequenc
viru
obtain
less
one
month
later
may
sarscoronaviru
main
proteas
structur
obtain
design
antisar
drug
decemb
vaccin
success
test
rhesu
macaqu
transmiss
sar
stop
aggress
quarantin
measur
possibl
rise
summer
temperatur
yet
definit
inform
anim
sourc
viru
sar
reemerg
human
april
pfizer
complet
us
acquisit
pharmacia
cement
pfizer
posit
world
largest
pharmaceut
compani
immedi
fallout
acquisit
chief
execut
pharmacia
fred
hassan
left
becom
chief
execut
scheringplough
compani
face
plummet
sale
legal
investig
disclosur
price
practic
hassan
brought
experi
turn
american
home
product
pharmacia
around
immedi
outlin
plan
involv
settl
legal
investig
us
secur
exchang
commiss
creation
team
execut
global
integr
manufactur
suppli
chain
cut
payrol
expens
may
disappoint
number
new
molecular
entiti
approv
saw
upward
trend
number
innov
highlight
approv
two
wide
anticip
firstinclass
drug
enfuvirtid
fuzeon
rochetrimeri
hiv
bortezomib
velcad
millennium
multipl
myeloma
enfuvirtid
approv
us
march
europ
may
linear
peptid
block
entri
cell
inhibit
viral
cell
membran
fusion
bortezomib
revers
inhibitor
proteasom
key
compon
degrad
unwant
misfold
protein
thought
overproduc
cancer
bortezomib
approv
basi
phase
ii
data
eight
year
discov
sign
regulatori
author
will
push
compound
larg
unmet
clinic
need
june
roch
launch
amplichip
world
first
pharmacogenom
microarray
clinic
applic
detect
polymorph
gene
encod
govern
metabol
around
prescript
drug
decis
affect
manufactur
gene
chip
fda
inform
roch
octob
chip
requir
fda
market
clearanc
approv
problem
roch
market
product
analytespecif
reagent
limit
detect
singl
analyt
set
reagent
laboratori
use
creat
diagnost
test
requir
premarket
applic
fda
believ
amplichip
assembl
devic
part
specif
test
system
requir
clinic
demonstr
safeti
effect
could
take
three
year
complet
juli
rna
interfer
rnai
seem
come
age
recent
discov
process
gene
silenc
small
rna
took
biolog
world
storm
due
novelti
eleg
effici
startup
quickli
form
creat
therapeut
applic
rnai
juli
two
biggest
compani
field
alnylam
ribopharma
merg
juli
also
saw
public
first
two
paper
publish
rais
question
specif
rnai
show
rna
use
silenc
gene
could
also
activ
gene
interferonrespons
pathway
trigger
global
inhibit
endogen
messeng
rna
translat
lead
apoptosi
effect
interferon
respons
vivo
yet
certain
mani
reason
propos
observ
exampl
high
concentr
rna
might
affect
natur
satur
system
nevertheless
septemb
merck
alnylam
enter
first
major
collabor
pharmaceut
rnai
compani
develop
therapeut
august
great
sad
saw
pass
away
three
wellrecogn
figur
pharmaceut
industri
loui
lasagna
founder
tuft
center
studi
drug
develop
wide
regard
creator
clinic
pharmacolog
die
august
lasagna
revolution
drug
evalu
regul
promot
random
control
clinic
trial
gold
standard
argu
essenti
consid
placebo
respons
trial
april
david
horrobin
die
one
central
theme
horrobin
research
role
fatti
acid
diseas
neurodegen
disord
passion
persuas
often
controversi
man
horrobin
founder
editor
medic
hypothes
allow
dissemin
new
idea
medicin
strong
voic
highlight
ineffici
pharmaceut
industri
final
paul
janssen
creator
janssen
pharmaceut
die
novemb
see
editori
issu
septemb
almost
two
year
discuss
world
trade
organ
final
agre
breakthrough
deal
give
poorer
countri
access
gener
medicin
traderel
aspect
intellectu
properti
right
trip
agreement
establish
doha
meet
novemb
gave
countri
face
public
health
crise
right
overrid
patent
vital
drug
order
gener
altern
domest
produc
emot
plea
african
negoti
overcam
lastminut
hitch
stress
million
african
die
aid
epidem
eightmonth
deadlock
talk
new
agreement
allow
poorer
countri
import
gener
drug
necessari
list
number
rich
countri
refrain
import
gener
lessrich
countri
import
circumst
extrem
urgenc
almost
instantli
brazil
author
import
gener
antiretrovir
canadian
govern
announc
late
septemb
would
amend
patent
law
allow
manufactur
gener
medicin
octob
nobel
prize
physiolog
medicin
award
paul
lauterbur
univers
illinoi
urbanachampaign
peter
mansfield
univers
nottingham
uk
contribut
develop
magnet
reson
imag
mri
medic
tool
lauterbur
adapt
nuclear
magnet
reson
nmr
introduc
gradient
magnet
field
mansfield
develop
use
gradient
magnet
field
show
signal
could
analys
made
possibl
develop
techniqu
use
clinic
imag
tool
raymond
damadian
protest
deserv
share
prize
show
cancer
healthi
tissu
distinguish
differ
nmr
signal
unsuccess
despit
spend
thousand
dollar
fullpag
advertis
us
newspap
ask
reader
protest
contact
nobel
committe
novemb
us
senat
final
pass
pediatr
research
equiti
act
give
us
fda
author
requir
pharmaceut
compani
test
treatment
use
children
around
threequart
drug
market
test
children
use
offlabel
clinician
obtain
dose
regimen
extrapol
data
adult
children
compani
requir
test
medic
children
fda
adopt
pediatr
rule
octob
feder
court
overturn
rule
ground
compani
could
requir
studi
indic
want
studi
fda
said
effect
reduc
children
indic
rather
disenfranchis
group
could
appli
exampl
ethnic
minor
pregnant
women
instead
appeal
fda
success
reli
congress
codifi
rule
law
decemb
contrast
shortterm
fortun
second
third
biggest
pharmaceut
compani
reveal
month
glaxosmithklin
held
first
r
day
sinc
merger
decemb
said
pipelin
grown
project
clinic
develop
includ
new
chemic
entiti
product
line
extens
vaccin
compound
potenti
becom
blockbust
howev
news
pipelin
result
share
dip
slightli
investor
disappoint
lack
latestag
compound
merck
refus
pursu
consolid
rout
found
unusu
situat
termin
two
phase
iii
compound
space
two
week
aprepit
substanc
p
antagonist
depress
peroxisom
proliferatoractiv
receptor
ppar
agonist
diabet
strengthen
pipelin
merck
recent
form
allianc
actelion
develop
renin
inhibitor
hypertens
neurogen
develop
small
molecul
target
vanilloid
receptor
pain
